ClinicalTrials.gg
CompletedNCT06911567Updated Feb 9, 2026

A Study to Assess New Formulations of TEV-56286

A Phase 1 interventional study of TEV-56286 Test and TEV-56286 Reference in Healthy Participants, sponsored by Teva Branded Pharmaceutical Products R&D LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Teva Branded Pharmaceutical Products R&D LLC (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The primary objective of the study is to assess the relative bioavailability of TEV-56286 test formulations compared to TEV-56286 reference product in healthy adult participants.

The secondary objective is to evaluate the safety and tolerability of TEV-56286.

The planned duration for each participant is approximately 70 days which includes a 45 day screening period.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Teva Branded Pharmaceutical Products R&D LLC is the lead sponsor of 24 studies on the registry; 7 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 18.5 kg/m2 to 32.0 kg/m2 (inclusive)
  • Females of agree to take appropriate measures to prevent pregnancy during the study
  • Males who do not have a documented vasectomy or are not congenitally sterile must agree to abstinence or use of barrier method with spermicide with female partner. Male participant who is having sexual intercourse with a woman of childbearing potential who is not currently pregnant will be advised of her requirement to use an additional highly effective method
  • NOTE - Additional criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical trial simultaneously
  • Females who are lactating, breastfeeding, or intends to become pregnant over the course of the study
  • History of alcohol, drug or any other substance, abuse, addiction or dependence in the last 12 months (except for caffeine)
  • Major trauma or surgery in the 2 months before screening or at any time between screening and the first dose of IMP, or surgery scheduled during the study or follow-up period
  • Donated blood or blood products (eg, white blood cells [WBCs], , etc.) within the 60 days before screening, or has donated blood or blood products at least twice within the 6 months before screening, or has donated plasma within 7 days of the screening visit or has received blood or blood products in the 6 weeks before screening
  • Personal or family history of arrhythmia, sudden unexplained death at a young age (before 40 years) in a first-degree relative, or long syndrome, or a personal history of syncope, or previous personal treatment for high blood pressure
  • NOTE - Additional criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Random sequence of test and reference formulations

    Drug: TEV-56286 Test · Drug: TEV-56286 Reference

  • Experimental
    Cohort 2

    Random sequence of test and reference formulations

    Drug: TEV-56286 Test · Drug: TEV-56286 Reference

Interventions

  • DrugTEV-56286 Test

    Administered orally

    Also known as: Emrusolmin

  • DrugTEV-56286 Reference

    Administered orally

    Also known as: Emrusolmin

06

What researchers measure

Primary outcomes

  1. Maximum Observed Drug Concentration (Cmax)

    Time frame: Up to Day 17

  2. Area Under the Drug Concentration-Time Curve from Time 0 to Last Measurable Drug Concentration [AUC(0-t)]

    Time frame: Up to Day 17

  3. Area Under the Drug Concentration-Time Curve from Time 0 to Infinity [AUC(0-inf)]

    Time frame: Up to Day 17

Secondary outcomes

  1. Number of participants with at least one treatment-emergent adverse event

    Time frame: Up to Day 26

  2. Number of participants who did not complete the trial due to an adverse event

    Time frame: Up to Day 26

07

Study locations

1 site
  • Teva Investigational Site 12141
    Miramar, Florida 33025, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in May 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Apr 4, 2025
StartActual
Mar 10, 2025
Primary completionActual
May 22, 2025
CompletionActual
Jun 2, 2025
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06911567
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Mar 10, 2025
Primary completion
May 22, 2025
Completion
Jun 2, 2025
Last update
Feb 9, 2026

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion